Print

Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation

Clinicaltrials.gov identifier:
NCT04673448 (https://clinicaltrials.gov/show/NCT04673448)


Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

About the Study

NOTE: This study is no longer recruiting people. 

 

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).

 

This Study is Open To:

NOTE: This study is no longer recruiting people. 

This Study is Not Open To:

NOTE: This study is no longer recruiting people. 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.